These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15948667)

  • 1. Systematic Analysis of Compounds Specifically Targeting Telomeres and Telomerase for Clinical Implications in Cancer Therapy.
    Lee HS; Carmena M; Liskovykh M; Peat E; Kim JH; Oshimura M; Masumoto H; Teulade-Fichou MP; Pommier Y; Earnshaw WC; Larionov V; Kouprina N
    Cancer Res; 2018 Nov; 78(21):6282-6296. PubMed ID: 30166419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomerase and its potential for therapeutic intervention.
    Phatak P; Burger AM
    Br J Pharmacol; 2007 Dec; 152(7):1003-11. PubMed ID: 17603541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perifosine as a potential novel anti-telomerase therapy.
    Holohan B; Hagiopian MM; Lai TP; Huang E; Friedman DR; Wright WE; Shay JW
    Oncotarget; 2015 Sep; 6(26):21816-26. PubMed ID: 26307677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zinc protoporphyrin binding to telomerase complexes and inhibition of telomerase activity.
    Zhu Z; Tran H; Mathahs MM; Fink BD; Albert JA; Moninger TO; Meier JL; Li M; Schmidt WN
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00882. PubMed ID: 34747573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics.
    Tao HY; Zhao CY; Wang Y; Sheng WJ; Zhen YS
    Int J Nanomedicine; 2024; 19():3805-3825. PubMed ID: 38708177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligonucleotides and microRNAs Targeting Telomerase Subunits in Cancer Therapy.
    Eckburg A; Dein J; Berei J; Schrank Z; Puri N
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase: a nexus between cancer nanotherapy and circadian rhythm.
    Ghosh PK; Rao MJ; Putta CL; Ray S; Rengan AK
    Biomater Sci; 2024 Apr; 12(9):2259-2281. PubMed ID: 38596876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is telomerase a viable target in cancer?
    Buseman CM; Wright WE; Shay JW
    Mutat Res; 2012 Feb; 730(1-2):90-7. PubMed ID: 21802433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic application of monoclonal antibodies in cancer: advances and challenges.
    Modjtahedi H; Ali S; Essapen S
    Br Med Bull; 2012; 104():41-59. PubMed ID: 23118261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma.
    Buckley AF; Kakar S
    Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):305-9. PubMed ID: 17721276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importin 13 promotes NSCLC progression by mediating RFPL3 nuclear translocation and hTERT expression upregulation.
    Zohud BA; Guo P; Zohud BA; Li F; Hao JJ; Shan X; Yu W; Guo W; Qin Y; Cai X
    Cell Death Dis; 2020 Oct; 11(10):879. PubMed ID: 33082305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Ionic Strength on Porphyrin Drugs Interaction with Quadruplex DNA Formed by the Promoter Region of C-myc and Bcl2 Oncogenes.
    Nagesh N; Sharma VK; Ganesh Kumar A; Lewis EA
    J Nucleic Acids; 2010; 2010():. PubMed ID: 20700417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.
    Aloysius MM; Mc Kechnie AJ; Robins RA; Verma C; Eremin JM; Farzaneh F; Habib NA; Bhalla J; Hardwick NR; Satthaporn S; Sreenivasan T; El-Sheemy M; Eremin O
    J Transl Med; 2009 Mar; 7():18. PubMed ID: 19298672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins.
    Wangpaichitr M; Wu C; You M; Kuo MT; Feun L; Lampidis T; Savaraj N
    Eur J Pharmacol; 2008 Sep; 591(1-3):124-7. PubMed ID: 18585380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase: a potential therapeutic target for cancer.
    Fletcher TM
    Expert Opin Ther Targets; 2005 Jun; 9(3):457-69. PubMed ID: 15948667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
    Rankin AM; Faller DV; Spanjaard RA
    Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for anti-neoplastic therapies based on telomere biology.
    Stewart SA; Hahn WC
    Curr Cancer Drug Targets; 2002 Mar; 2(1):1-17. PubMed ID: 12188917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomeres and telomerase: Pharmacological targets for new anticancer strategies?
    Pendino F; Tarkanyi I; Dudognon C; Hillion J; Lanotte M; Aradi J; Ségal-Bendirdjian E
    Curr Cancer Drug Targets; 2006 Mar; 6(2):147-80. PubMed ID: 16529544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of telomerase and viruses interaction in cancer development, and telomerase-dependent therapeutic approaches.
    Salimi-Jeda A; Badrzadeh F; Esghaei M; Abdoli A
    Cancer Treat Res Commun; 2021; 27():100323. PubMed ID: 33530025
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.